Displaying drugs 15701 - 15725 of 15761 in total
Acarbose Derived Hexasaccharide
Experimental
Matched Iupac: … -2-en-1-yl]amino}-3,4-dihydroxy-6-methyloxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl …
Ganglioside GM1
Investigational
Matched Iupac: … hydroxymethyl)oxan-4-yl]oxy}-5-acetamido-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid …
Carphenazine
Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses.
Withdrawn
CRA_1801
Experimental
105AD7
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.
Investigational
Acetylcysteine zidrimer
Investigational
Bis(5-Amidino-2-Benzimidazolyl)Methanone
Experimental
4-Iodobenzo[B]Thiophene-2-Carboxamidine
Experimental
ALS-08
ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
Investigational
Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone
Experimental
5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
Experimental
NRP409
NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
Investigational
Dapansutrile
Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).
Investigational
PH94B
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
Atpenin A5
Experimental
Tin protoporphyrin IX
Investigational
ZK-805623
Experimental
AP5346
AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational
Displaying drugs 15701 - 15725 of 15761 in total